Overview
Michael Melia is an Infectious Disease provider in Baltimore, Maryland. Dr. Melia is rated as an Experienced provider by MediFind in the treatment of Allergic Bronchopulmonary Aspergillosis. His top areas of expertise are Lyme Disease, Hepatitis C, Allergic Bronchopulmonary Aspergillosis, and HIV/AIDS. Dr. Melia is currently accepting new patients.
His clinical research consists of co-authoring 41 peer reviewed articles. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Allergic Bronchopulmonary Aspergillosis.
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- OTHER MEDICARE PART D
- PPO
- HMO
- POS
- PPO
- EPO
- HMO
- PPO
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- EPO
- HMO
- PPO
- HMO
- INDEMNITY
- POS
- PPO
- HMO
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE-MEDICAID PLAN
- OTHER MEDICAID
- STATE MEDICAID
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE PART D
- INSURANCE PLAN
- MEDICARE MAPD
- OTHER COMMERCIAL
- PPO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE ASSISTANCE PROGRAM
- MEDICARE MAPD
- MEDICARE SNP
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
600 N Wolf St, Baltimore, MD 21287
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Johns Hopkins University
Gail Berkenblit is an Infectious Disease provider in Baltimore, Maryland. Dr. Berkenblit is rated as an Advanced provider by MediFind in the treatment of Allergic Bronchopulmonary Aspergillosis. Her top areas of expertise are Hepatitis C, Hepatitis, HIV/AIDS, and Myelitis.
John Reinhardt, MD
John Reinhardt is an Infectious Disease specialist and an Internal Medicine provider in Newark, Delaware. Dr. Reinhardt has been practicing medicine for over 50 years and is rated as an Advanced provider by MediFind in the treatment of Allergic Bronchopulmonary Aspergillosis. His top areas of expertise are Allergic Bronchopulmonary Aspergillosis, Lymphangitis, Pneumocystis Jiroveci Pneumonia, and Nontuberculous Mycobacterial Lung Disease.
Johns Hopkins University
Robin Avery is an Infectious Disease provider in Baltimore, Maryland. Dr. Avery is rated as a Distinguished provider by MediFind in the treatment of Allergic Bronchopulmonary Aspergillosis. Her top areas of expertise are Cytomegalic Inclusion Disease, Cytomegalovirus Infection, COVID-19, and Severe Acute Respiratory Syndrome (SARS). Dr. Avery is currently accepting new patients.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Advanced
- Lyme DiseaseDr. Melia isAdvanced. Learn about Lyme Disease.
- Experienced
- AIDS Dementia ComplexDr. Melia isExperienced. Learn about AIDS Dementia Complex.
- AIDS Dysmorphic SyndromeDr. Melia isExperienced. Learn about AIDS Dysmorphic Syndrome.
- Allergic Bronchopulmonary Aspergillosis
- ArachnoiditisDr. Melia isExperienced. Learn about Arachnoiditis.
- CellulitisDr. Melia isExperienced. Learn about Cellulitis.
- COVID-19Dr. Melia isExperienced. Learn about COVID-19.